Treating Opioid Misuse Via Mindfulness-Based Just-in-Time Adaptive Intervention (MORE-JITAI)
Reating Opioid Misuse Via Mindfulness-Based Just-in-Time Adaptive Intervention
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- Center on Mindfulness and Integrative Health Intervention Development
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Current chronic pain diagnosis determined by physician assessment (including but not limited to ICD-9 diagnoses 338.0, 338.21, 338.22, 338.28, 338.29, 338.4)
- Current use of prescription opioid agonist or mixed agonist-antagonist analgesics for >90 days
- Willingness to participate in study interventions and assessments
Exclusion Criteria:
- Prior experience with Mindfulness-Based Stress Reduction, Mindfulness-Based Cognitive Therapy, or Mindfulness-Based Relapse Prevention
- Active suicidality, schizophrenia, psychotic disorder
- Presence of clinically unstable systemic illness judged to interfere with treatment
- No access to internet (which will prevent telehealth-based treatment)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Mindfulness-Oriented Recovery Enhancement+JITAI
Participants will attend a telehealth Mindfulness-Oriented Recovery Enhancement (MORE) group plus mindfulness JITAI weekly for eight weeks.
|
Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative intervention strategy targeting mechanisms of pain and opioid misuse.
JITAI involves stress-triggered reminders to practice mindfulness skills.
|
|
Active Comparator: Supportive Psychotherapy
Participants will attend a telehealth supportive psychotherapy group weekly for eight weeks.
|
A supportive psychotherapy group will allow participants to express emotions, share experiences, and receive social support under the guidance of a skilled therapist.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in momentary craving
Time Frame: Baseline through 1-month follow-up
|
Craving measured by numeric rating scale via ecological momentary assessments (min 0, max 10, with higher scores meaning more craving)
|
Baseline through 1-month follow-up
|
|
Change in momentary pain: numeric rating scale
Time Frame: Baseline through 1-month follow-up
|
Pain measured by numeric rating scale via ecological momentary assessments (min 0, max 10, with higher scores meaning more pain)
|
Baseline through 1-month follow-up
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in momentary positive affect
Time Frame: Baseline through 1-month follow-up
|
Positive affect measured by numeric rating scale via ecological momentary assessments (min 0, max 10, with higher scores meaning more positive affect)
|
Baseline through 1-month follow-up
|
|
Change in momentary stress
Time Frame: Baseline through 1-month follow-up
|
Stress measured by numeric rating scale via ecological momentary assessments (min 0, max 10, with higher scores meaning more stress)
|
Baseline through 1-month follow-up
|
|
Change in heart rate variability
Time Frame: Baseline through 1-month follow-up
|
Changes in heart rate variability (HRV) measured via ambulatory HRV assessment
|
Baseline through 1-month follow-up
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in opioid misuse
Time Frame: Baseline through post-treatment (week 8)
|
Scores on Current Opioid Misuse Measure, with higher scores indicating higher opioid misuse (min 0, max 68)
|
Baseline through post-treatment (week 8)
|
|
Change in chronic pain symptoms
Time Frame: Baseline through post-treatment (week 8)
|
Scores on Brief Pain Inventory, with higher scores indicating higher pain severity (min 0, max 10)
|
Baseline through post-treatment (week 8)
|
|
Change in opioid dose
Time Frame: Baseline through post-treatment (week 8)
|
Opioid dose as assessed with Timeline Followback Procedure
|
Baseline through post-treatment (week 8)
|
|
Change in self-transcendence
Time Frame: Baseline through post-treatment (week 8)
|
Self-transcendence measured by Nondual Awareness Dimensional Assessment, with higher scores indicating higher self-transcendence (min 13, max 65)
|
Baseline through post-treatment (week 8)
|
|
Change in mindful reinterpretation of pain sensations
Time Frame: Baseline through post-treatment (week 8)
|
Mindful reinterpretation of pain sensations measured by the Mindful Reinterpretation of Pain Sensations Scale, with higher scores indicating higher reinterpretation of pain sensations (min 0, max 45)
|
Baseline through post-treatment (week 8)
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 00078615.2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.